Hugo ten Cate Selected Research

Shwartzman Phenomenon (Shwartzman Reaction)

11/2007	Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation.
9/2007	Gene expression profiling identifies C/EBPdelta as a candidate regulator of endotoxin-induced disseminated intravascular coagulation.
8/2006	Low dose endotoxin priming is accountable for coagulation abnormalities and organ damage observed in the Shwartzman reaction. A comparison between a single-dose endotoxemia model and a double-hit endotoxin-induced Shwartzman reaction.
1/2003	Disseminated intravascular coagulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hugo ten Cate Research Topics

Disease

20	Inflammation (Inflammations) 01/2014 - 05/2002
16	Atherosclerosis 01/2014 - 07/2002
13	Thrombosis (Thrombus) 11/2013 - 11/2003
8	Sepsis (Septicemia) 01/2014 - 05/2002
7	Hemorrhage 01/2016 - 11/2008
7	Atherosclerotic Plaque (Atheroma) 02/2014 - 08/2008
7	Disseminated Intravascular Coagulation 08/2011 - 01/2003
7	Infections 02/2010 - 05/2002
6	Wounds and Injuries (Trauma) 01/2016 - 09/2007
5	Cardiovascular Diseases (Cardiovascular Disease) 08/2015 - 06/2009
5	Thrombophilia 01/2014 - 06/2004
5	Myocardial Infarction 01/2014 - 07/2002
5	Venous Thromboembolism 12/2013 - 11/2003
5	Type 2 Diabetes Mellitus (MODY) 05/2012 - 09/2004
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2016 - 08/2008
4	Peripheral Arterial Disease 01/2014 - 07/2002
4	Ischemic Stroke 01/2014 - 07/2002
4	Venous Thrombosis (Deep-Vein Thrombosis) 08/2008 - 07/2002
4	Shwartzman Phenomenon (Shwartzman Reaction) 11/2007 - 01/2003
3	Myocardial Ischemia (Ischemic Heart Diseases) 01/2014 - 10/2003
3	Neoplasms (Cancer) 08/2012 - 01/2004
3	Hypertension (High Blood Pressure) 05/2012 - 12/2005
3	Reperfusion Injury 07/2010 - 09/2007
2	Pulmonary Embolism 07/2015 - 01/2012
2	Essential Thrombocythemia 07/2013 - 07/2009
2	Fever (Fevers) 02/2010 - 02/2010
2	Carotid Artery Thrombosis 10/2007 - 11/2003
2	Endotoxemia 08/2006 - 02/2006
2	Multiple Organ Failure (MODS) 06/2005 - 01/2003
2	Vascular System Injuries 09/2004 - 01/2003
1	Thrombocytopenia (Thrombopenia) 02/2016
1	Multiple Trauma (Multiple Injuries) 01/2016
1	Stroke (Strokes) 08/2015
1	Coronary Disease (Coronary Heart Disease) 08/2015
1	Vascular Diseases (Vascular Disease) 08/2015
1	Embolism (Embolus) 12/2014
1	Hemophilia A (Haemophilia) 02/2014
1	Vasculitis (Vasculitides) 12/2013
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 12/2013
1	Polycythemia Vera 07/2013
1	Hypercholesterolemia 05/2013

Drug/Important Bio-Agent (IBA)

22	Thrombin FDA Link 08/2015 - 05/2002
11	AnticoagulantsIBA 01/2016 - 10/2003
9	Thromboplastin (Tissue Factor)IBA 08/2012 - 10/2003
7	Peptide Hydrolases (Proteases)FDA Link 11/2014 - 11/2007
7	Proteins (Proteins, Gene)FDA Link 05/2012 - 06/2005
6	Dacarbazine (DIC)FDA LinkGeneric 11/2007 - 01/2003
5	Hemostatics (Antihemorrhagics)IBA 01/2014 - 05/2002
4	Dabigatran FDA Link 01/2016 - 05/2012
4	Prothrombin (Factor II)IBA 01/2016 - 07/2002
4	fibrin fragment D (D-dimer)IBA 12/2014 - 01/2012
4	Apolipoproteins E (ApoE)IBA 01/2014 - 05/2012
4	EndotoxinsIBA 10/2007 - 02/2006
3	Biomarkers (Surrogate Marker)IBA 01/2014 - 08/2008
3	Protein CIBA 01/2014 - 08/2006
3	CoagulantsIBA 01/2013 - 07/2010
3	Vitamin K FDA Link 01/2013 - 01/2012
3	von Willebrand FactorIBA 01/2013 - 01/2005
3	FibrinIBA 05/2012 - 01/2008
3	C-Reactive ProteinIBA 05/2012 - 01/2005
3	Interleukin-6 (Interleukin 6)IBA 08/2008 - 09/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2008 - 09/2007
3	ThrombomodulinIBA 08/2008 - 11/2003
2	Heparin (Liquaemin)FDA LinkGeneric 02/2016 - 01/2013
2	RivaroxabanIBA 01/2014 - 05/2012
2	Endothelial Protein C ReceptorIBA 01/2014 - 09/2004
2	ApolipoproteinsIBA 01/2014 - 01/2013
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 07/2013 - 01/2009
2	AntigensIBA 05/2013 - 08/2008
2	prolyl-proline (Pro-Pro)IBA 01/2013 - 11/2003
2	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2013 - 06/2005
2	Factor XII (Hageman Factor)IBA 08/2012 - 09/2008
2	EnzymesIBA 08/2012 - 12/2003
2	Glucose (Dextrose)FDA LinkGeneric 05/2012 - 07/2009
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2010 - 02/2005
2	Advanced Glycation End ProductsIBA 07/2009 - 09/2004
2	Biological ProductsIBA 06/2009 - 08/2008
2	Blood Coagulation Factors (Coagulation Factor)IBA 01/2009 - 12/2003
2	Kallikreins (Kallikrein)IBA 09/2008 - 12/2005
2	Factor XI (Plasma Thromboplastin Antecedent)IBA 09/2008 - 06/2004
2	AntibodiesIBA 08/2008 - 03/2003
2	LipopolysaccharidesIBA 12/2007 - 02/2006
2	ferric chlorideIBA 10/2007 - 11/2003
2	CreatinineIBA 09/2007 - 06/2005
2	CytokinesIBA 10/2003 - 05/2002
1	Cytochrome P-450 CYP2C19IBA 01/2016
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2016
1	idarucizumabIBA 09/2015
1	Pravastatin (Pravachol)FDA LinkGeneric 08/2015
1	PAR-1 ReceptorIBA 01/2014
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 12/2013
1	Adenosine Diphosphate (ADP)IBA 07/2013
1	Purinergic P2 Receptors (ADP Receptor)IBA 07/2013
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 05/2013
1	Warfarin (Coumadin)FDA LinkGeneric 01/2013

Therapy/Procedure

7	Therapeutics 01/2016 - 02/2005
2	Glycemic Control 05/2012 - 05/2010
1	Percutaneous Coronary Intervention 01/2016
1	Aftercare (After-Treatment) 07/2015
1	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2013